Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $150.00, for a total value of $1,500,000.00. Following the completion of the sale, the chief financial officer owned 43,681 shares of the company's stock, valued at approximately $6,552,150. This represents a 18.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Glaukos Trading Up 1.5%
Shares of Glaukos stock opened at $152.89 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The company has a market capitalization of $8.98 billion, a P/E ratio of -46.61 and a beta of 0.75. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $154.61. The company's fifty day moving average is $131.05 and its two-hundred day moving average is $120.19.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.12. The firm had revenue of $150.57 million for the quarter, compared to analysts' expectations of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm's revenue for the quarter was up 41.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.22) EPS. Analysts forecast that Glaukos Corporation will post -0.57 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. Wealth Alliance LLC raised its position in shares of Glaukos by 4.5% during the 1st quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier's stock worth $247,000 after purchasing an additional 98 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Glaukos by 9.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier's stock worth $158,000 after acquiring an additional 122 shares during the period. Larson Financial Group LLC lifted its position in Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 132 shares during the last quarter. CWM LLC raised its holdings in shares of Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier's stock valued at $80,000 after buying an additional 143 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Glaukos by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier's stock worth $947,000 after buying an additional 144 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
GKOS has been the topic of a number of research reports. Stifel Nicolaus set a $170.00 price objective on Glaukos in a report on Thursday, April 30th. Piper Sandler reissued an "overweight" rating and issued a $165.00 price objective on shares of Glaukos in a research report on Wednesday, July 1st. Wells Fargo & Company increased their target price on Glaukos from $135.00 to $138.00 and gave the company an "overweight" rating in a research note on Thursday, April 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Glaukos in a research report on Tuesday, April 21st. Finally, William Blair reissued an "outperform" rating on shares of Glaukos in a research report on Tuesday, May 26th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $151.62.
Read Our Latest Stock Report on Glaukos
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
